Ingrid Zhang is taking the helm of the cancer therapy company, filling a post vacant since…
Category: Environment
Chinese biotech companies are training their sights on one of the most lucrative medicines: GLP-1s
Long a maker of low-end generic drugs, the country is now home to biotech firms that…
Big Pharma chiefs constantly hunt for promising biotech drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive, panic-driven mistakes.
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping hungry can lead…
Trump Administration Moves to Spare Space Companies From Environmental Reviews
The government reviews study the impact of rocket launches and reentries on surrounding wildlife and their…
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
The move marks Ipsen’s second acquisition this week after its agreement to take over Kartos Therapeutics,…
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
The move marks Ipsen’s second acquisition this week after its agreement to take over Kartos Therapeutics,…
Heard on the Street: Johnson & Johnson seems to have perfected the art of the biotech deal, but there’s a catch
Partnership strategy has produced great pharma bargains—and left the company exposed.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
Palestinians use recycling as Israel’s restrictions trigger a trash crisis
Palestinians in the West Bank live amid garbage following Israeli restrictions. Two Palestinian entrepreneurs are trying…
Biotech Investors Are Tuning Out the MAHA Chaos
The Food and Drug Administration is still in turmoil, but Wall Street no longer cares.